<DOC>
	<DOC>NCT02031861</DOC>
	<brief_summary>The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran) with nifedipine controlled-release tablets (Adalat）in the treatment of mild to moderate essential hypertension.</brief_summary>
	<brief_title>Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>Voluntarily participate and must sign informed consent form Mild to moderate essential hypertension (SBP 140179 mmHg and/or DBP 90109 mmHg) Average DBP measured by 24hour ambulatory blood pressure monitoring (ABPM) ≥80 mmHg Secondary hypertension and malignant hypertension Pregnant or nursing women, or patients that cannot guarantee to take effective contraception measures Baseline SBP≥180 mmHg or DBP≥110 mmHg, or patients with cerebral, cardiac or renal complications Have following complications: cerebrovascular accident within 6 months, myocardial infarction or cardiac failure, macroaneurysm or dissecting aneurysm, definite angina, AV block of grade 2 or higher, sick sinus syndrome, atrial fibrillation or other malignant arrhythmia Clinical significant diseases of heart, lung, liver, kidney and hematologic system or malignant tumors, HIV infection, uncontrolled diabetes (fasting blood glucose ≥7.0 mmol/L, 2hour postprandial blood glucose ≥7.8 mmol/L) Kock pouch Sever gastrointestinal stenosis Abnormal laboratory values with clinical significance, including serum potassium &lt;3.5 or &gt;5.5 mmol/L, glutamicpyruvic transaminase (ALT) or glutamic oxalacetic transaminase (AST) &gt;2fold upper limit of normal (ULN), Cr &gt;ULN Uric acid &gt;ULN with the diagnosis of gout Gastrointestinal abnormalities or surgery that may interfere with drug absorption Hyperthyroidism or hypothyroidism Allergic to any ingredient or metabolite of investigational drug or drugs of similar structure Heavy smokers (&gt;25 cigarettes every day), alcoholics (&gt;250 ml liquor every day), drug addicts Psychological diseases, acrasia, cannot express explicitly Patients whose mood may be affected by variations in blood pressure, which in turn increases blood pressure Anxiety disorders, depression or cannot follow study protocol BMI &gt;30 Night shift, irregular sleep patterns or insomnia participate in other clinical trials within 3 months other conditions that investigators consider unsuitable for participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>